Q-omics provides the consensus-scored MYL7 profile across patient tissues and cancer cell-line models. MYL7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MYL7 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, MYL7 RNA expression shows 11,173 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, BRCA, and TGCT as cancer lineages where MYL7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYL7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYL7 survival associations across molecular data types. MYL7 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYL7 RNA expression–survival associations across cancer types. High MYL7 expression shows unfavorable associations in MESO, LGG, ACC, KIRC and OV, but favorable associations in THYM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MYL7 RNA expression.
This table summarizes MYL7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MYL7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYL7 shows lower tumor expression in BRCA, COAD, UCEC and KICH and higher tumor expression in HNSC and LUSC. The BRCA box plot shows higher MYL7 RNA expression in normal versus tumor tissue (log2 FC = −1.258, t-test p < 0.001).
This table shows molecular features associated with MYL7 in patient tissues and cancer cell lines. In patient samples, MYL7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MYL7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
